Details
Stereochemistry | RACEMIC |
Molecular Formula | C20H15Cl3N2OS.HNO3 |
Molecular Weight | 500.783 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[N+]([O-])=O.ClC1=CC=C(C(CN2C=CN=C2)OCC3=CSC4=C3C=CC=C4Cl)C(Cl)=C1
InChI
InChIKey=HAAITRDZHUANGT-UHFFFAOYSA-N
InChI=1S/C20H15Cl3N2OS.HNO3/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22;2-1(3)4/h1-8,11-12,19H,9-10H2;(H,2,3,4)
Molecular Formula | C20H15Cl3N2OS |
Molecular Weight | 437.77 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | HNO3 |
Molecular Weight | 63.0128 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.rxlist.com/ertaczo-drug.htm
https://www.drugs.com/mtm/sertaconazole-topical.html
http://www.wikidoc.org/index.php/Sertaconazole
Curator's Comment: description was created based on several sources, including:
http://www.rxlist.com/ertaczo-drug.htm
https://www.drugs.com/mtm/sertaconazole-topical.html
http://www.wikidoc.org/index.php/Sertaconazole
Sertaconazole is a azole antifungal that is FDA approved for the treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. Sertaconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Common adverse reactions include contact dermatitis, dry skin, burning skin and application site skin tenderness.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1780 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | ERTACZO Approved UseERTACZO® (sertaconazole nitrate) Cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum (see CLINICAL STUDIES Section). Launch Date2003 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.79 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19889586 |
300 mg single, vaginal dose: 300 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
SERTACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
43.31 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19889586 |
300 mg single, vaginal dose: 300 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
SERTACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20.25 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/19889586 |
300 mg single, vaginal dose: 300 mg route of administration: Vaginal experiment type: SINGLE co-administered: |
SERTACONAZOLE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1% |
SERTACONAZOLE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro comparative study of the fungistatic and fungicidal activity of sertaconazole and other antifungals against Candida albicans. | 1992 May |
|
In vitro antifungal activity of sertaconazole. | 1992 May |
|
In vitro activity of sertaconazole. | 1992 May |
|
In-vitro antifungal activity of sertaconazole, econazole, and bifonazole against Candida spp. | 1995 Oct |
|
Antifungal activity of sertaconazole in vitro against clinical isolates of Candida spp. | 1996 Mar-Apr |
|
Comparative study of antifungal activity of sertaconazole, terbinafine, and bifonazole against clinical isolates of Candida spp., Cryptococcus neoformans and dermatophytes. | 1997 Nov-Dec |
Sample Use Guides
Cream should be applied to the affected and immediate surrounding area(s) twice daily for 4 weeks.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9395851
MIC for Candida parapsilosis (0.26 mg/l) demonstrated a higher activity of sertaconazole against this species, in contrast to Candida tropicalis (MIC 1.49 mg/l). Against dermatophytes, MIC for sertaconazole was MIC 0.41 mg/l and against Cryptococcus neoformans yeasts - arithmetic mean MIC 1.24 mg/l.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:30 GMT 2025
by
admin
on
Mon Mar 31 18:00:30 GMT 2025
|
Record UNII |
1DV05410M5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
236601
Created by
admin on Mon Mar 31 18:00:30 GMT 2025 , Edited by admin on Mon Mar 31 18:00:30 GMT 2025
|
PRIMARY | RxNorm | ||
|
1DV05410M5
Created by
admin on Mon Mar 31 18:00:31 GMT 2025 , Edited by admin on Mon Mar 31 18:00:31 GMT 2025
|
PRIMARY | |||
|
DBSALT001382
Created by
admin on Mon Mar 31 18:00:31 GMT 2025 , Edited by admin on Mon Mar 31 18:00:31 GMT 2025
|
PRIMARY | |||
|
DTXSID2045529
Created by
admin on Mon Mar 31 18:00:31 GMT 2025 , Edited by admin on Mon Mar 31 18:00:31 GMT 2025
|
PRIMARY | |||
|
C47716
Created by
admin on Mon Mar 31 18:00:30 GMT 2025 , Edited by admin on Mon Mar 31 18:00:30 GMT 2025
|
PRIMARY | |||
|
200103
Created by
admin on Mon Mar 31 18:00:30 GMT 2025 , Edited by admin on Mon Mar 31 18:00:30 GMT 2025
|
PRIMARY | |||
|
SUB04374MIG
Created by
admin on Mon Mar 31 18:00:30 GMT 2025 , Edited by admin on Mon Mar 31 18:00:30 GMT 2025
|
PRIMARY | |||
|
1DV05410M5
Created by
admin on Mon Mar 31 18:00:31 GMT 2025 , Edited by admin on Mon Mar 31 18:00:31 GMT 2025
|
PRIMARY | |||
|
m9874
Created by
admin on Mon Mar 31 18:00:30 GMT 2025 , Edited by admin on Mon Mar 31 18:00:30 GMT 2025
|
PRIMARY | Merck Index | ||
|
99592-39-9
Created by
admin on Mon Mar 31 18:00:30 GMT 2025 , Edited by admin on Mon Mar 31 18:00:30 GMT 2025
|
PRIMARY | |||
|
83687
Created by
admin on Mon Mar 31 18:00:31 GMT 2025 , Edited by admin on Mon Mar 31 18:00:31 GMT 2025
|
PRIMARY | |||
|
100000084931
Created by
admin on Mon Mar 31 18:00:31 GMT 2025 , Edited by admin on Mon Mar 31 18:00:31 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201196
Created by
admin on Mon Mar 31 18:00:30 GMT 2025 , Edited by admin on Mon Mar 31 18:00:30 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |